Protease inhibitors for patients with HIV-1 infection a comparative overview

P and T

Volumn 36, Issue 6, 2011, Pages 332-345

  Hughes, Peter J ^a   Cretton Scott, Erika ^a   Teague, Ami ^a   Wensel, Terri M ^a  

^a Samford University   (United Kingdom)

Author keywords

HIV; Human immunodeficiency virus; Protease inhibitor

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ALFUZOSIN; ALMOTRIPTAN; ALPRAZOLAM; AMIODARONE; AMPRENAVIR; ATAZANAVIR; ATOMOXETINE; ATORVASTATIN; BECLOMETASONE DIPROPIONATE; BUPRENORPHINE; DARUNAVIR; DELAVIRDINE; DIDANOSINE; DISULFIRAM; DRONEDARONE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; EPLERENONE; ETRAVIRINE; EVEROLIMUS; FESOTERODINE; FLECAINIDE; FLUINDOSTATIN; FLUTICASONE PROPIONATE PLUS SALMETEROL; FOSAMPRENAVIR; INDINAVIR; IRINOTECAN; KETOCONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MEVINOLIN; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; NILOTINIB; NISOLDIPINE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PITAVASTATIN; PRAVASTATIN; PROPAFENONE; PROTEINASE INHIBITOR; RALTEGRAVIR; RANOLAZINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; ROMIDEPSIN; ROSUVASTATIN; SAQUINAVIR; SAXAGLIPTIN; SILDENAFIL; SILODOSIN; SIMVASTATIN; STAVUDINE; TADALAFIL; TAMOXIFEN; TAMSULOSIN; TENOFOVIR DISOPROXIL; THIORIDAZINE; TIPRANAVIR; TOLVAPTAN; TOPOTECAN; TRIAMCINOLONE ACETONIDE; TRIAZOLAM; UNINDEXED DRUG; VARDENAFIL; VORICONAZOLE; ZIDOVUDINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSAGE FORM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG SAFETY; ENZYME INHIBITION; FATIGUE; FEVER; GENETIC POLYMORPHISM; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; JAUNDICE; LIVER TOXICITY; NAUSEA; PANCREATITIS; RASH; REVIEW; VOMITING;

EID: 79959982092     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Atazanavir (Reyataz), package insert. Princeton, N.J.: Bristol- Myers Squibb; April 2010.
2. Darunavir (Prezista), package insert. Raritan, N.J.: Tibotec; April 2010.
3. Fosamprenavir (Lexiva), package insert. Triangle Park, N.C.: GlaxoSmithKline; April 2010.
4. Indinavir (Crixivan), package insert. Whitehouse Station, N.J.: Merck; April 2010.
5. Lopinavir/ritonavir (Kaletra), package insert. North Chicago, Ill.: Abbott; April 2010.
6. Nelfinavir (Viracept), package insert. La Jolla, Calif: Agouron; September 2008.
7. Ritonavir (Norvir), package insert. North Chicago, Ill: Abbott; April 2010.
8. Saquinavir (Invirase), package insert. South San Francisco, Calif.: Genentech; October 2010.
9. Tipranavir (Aptivus), package insert. Ridgefield, Conn: Boeh - ringer Ingelheim; May 2010.
10. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. January 10, 2011. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed January 24, 2011.
11. American Hospital Formulary Service. Samford University. Available at: www.crlonline.com.ezproxy.samford.edu/crlsql/servlet/crlonline. Accessed June 23, 2010.
12. Clinical Pharmacology. Samford University. Available at: http://clinicalpharmacology-ip.com.ezproxy.samford.edu/Forms/onograph/monograph.aspx?cpnum=551&sec=mondesc. Accessed June 23, 2010.
13. Micromedex. Samford University. Available at: www.thomsonhc.com.ezproxy.samford.edu/hcs/librarian/nd_t/hcs/nd_pr/main/cs/b56d7e/duplicationshieldsync/8947be/nd_pg/prih/nd_b/hcs/sbk/2/nd_P/Main/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/1713/ContentSetId/31/SearchTerm/ritonavir%20/SearchOption/BeginWith. Accessed June 23, 2010.
14. Tomasselli A, Heinrikson R. Targeting the HIV-protease in AIDS therapy: A current clinical perspective. Biochem Biophys Acta 2000;1477:189-214.
15. Wensing A, van Maarseveen N, Nijhuis M. Fifteen years of HIV protease inhibitors: Raising the barrier to resistance. Antiviral Res 2010;85:59-74.
16. Brik A, Wong C-H. HIV-1 protease: Mechanism and drug discovery. Org Biomol Chem 2008;1:5-14.
17. Lexi-Comp Online. Samford University. Available at: www.crlonline.com.ezproxy.samford.edu/crlsql/servlet/crlonline. Accessed May 20, 2010.
18. Etravirine (Intelence), package insert. Raritan, N.J.: Tibotec; December 2010.
19. HIV InSite. University of California, San Francisco. Available at: http://hivinsite.ucsf.edu/InSite?page=md-rr-31. Accessed December 31, 2010.
20. Enfuvirtide (Fuzeon), package insert. South San Francisco, Calif. Genentech; February 2010.
21. Raltegravir (Isentress), package insert. Whitehouse Station, N.J.: Merck; November 2010.
22. Maraviroc (Selzentry), package insert. New York: Pfizer; May 2010.
23. Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res 2010; 85(1):190-200.
24. Mendoza C, Valer L, Ribera E, Barreiro P, et al. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. HIV Clin Trials 2006;7(4):163-171.
25. Santoro MM, Bertoli A, Lorenzini P, et al. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: The CARe study. AIDS Patient Care STDs 2008;22(1):7-16.
26. Horberg M, Klein D, Hurley, et al. Efficacy and safety of ritonavirboosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials 2008;9(6):367-374.
27. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ ritonavir in patients with multiple virologic failures. AIDS 2006;20(5):711-718.
28. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53(3):323-332.
29. Soriano V, Garcia-Gasco P, Vispo E, et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trial. J Antimicrob Chemother 2008;61(1):200-205.
30. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification of atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006;296(7):806-814.
31. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36(5):1011-1019.
32. Pozniak A, Opravil M, Beatty G, Hill A, et al. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2. AIDS Res Hum Retroviruses 2008; 24(10):1275-1280.
33. Pellegrin I, Wittkop L, Joubert LM, et al. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (Predizista study). Antivir Ther 2008;13(2):271-279.
34. Katlama C, Esposito R, Gatell JM, et al. POWER 1 study group. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21(4):395-402.
35. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of oncedaily darunavir/ritonavir versus lopinavir/ritonavir in treatmentnaive HIV-1-infected patients at week 48. AIDS 2008;22(12):1389-1397.
36. De Meyer SM, Spinosa-Guzman S, Vangeneugden TJ, et al. Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV- infected treatment-experienced patients with no baseline resistanceassociated mutations to darunavir. J Acquir Immune Defic Syndr 2008;49(2):179-182.
37. De Meyer S, Lathouwers E, Dierynck I, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatmentexperienced patients. AIDS 2009;23(14):1829-1840.
38. Hicks CB, DeJesus E, Sloan LM, et al. Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. AIDS Res Hum Retrovirues 2009;25(4):395-403.
39. Smith KY, Weinberg WG, DeJesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/ emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008;5:5.
40. Gathe JC, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twicedaily nelfinavir in naive HIV-1-infected patients. AIDS 2004;18(11): 1529-1537.
41. Molina JM, Ait-Khaled M, Rinaldi R, et al. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): A randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. J Anti - microb Chemother 2009;64(2):398-410.
42. Eron J, Yeni P, Gathe J, et al. The KLEAN study of fosamprenavir- ritonavir versus lopinavir-ritonavir, each in combination with abacavir- lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial. Lancet 2006;368(9534): 476-482.
43. Landman R, Capitant C, Descamps D, et al. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviralnaive HIV-1-infected patients: The 2IP ANRS 127 study. J Anti - microb Chemother 2009;64(1):118-125.
44. Boyd MA, Siangphoe U, Ruxrungtham K, et al. Indinavir/ritonavir 800/100 mg b.i.d. and efavirenz 600 mg daily in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Med 2005; 6(6):410-420.
45. Dragsted UB, Gerstoft J, Pedersen C, et al., and the MaxCmin1 Trial Group. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 Trial. J Infect Dis 2003; 188(5): 635-642.
46. Hirsch M, Steigbigel R, Staszewski S, et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis 1999;180(3):659-665.
47. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341(25): 1865-1873.
48. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine- zidovudine vs. indinavir-lamivudine-zidovudine in antiretro - viral-naive HIV-infected adults: A randomized equivalence trial. JAMA 2001;285(9):1155-1163.
49. Fischl MA, Ribaudo HJ, Collier AC, et al. Adult AIDS Clinical Trials Group 388 Study Team. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 2003;188(5): 625-634.
50. Dragsted UB, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1- infected patients: The MaxCmin2 trial. Antivir Ther 2005;10(6): 735-743.
51. De Luca A, Cozzi-Lepri A, Antinori A, et al. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretro - viral therapy: A non-randomized comparison. Antivir Ther 2006; 11(5):609-618.
52. Domingo P, Suárez-Lozano I, Torres F, et al. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleo - side analogues: The SUSKA study, a non-randomized comparison from the VACH cohort. J Antimicrob Chemother 2008;61(6):1348-1358.
53. Pulido F, Delgado R, Pérez-Valero I, et al. Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression. J Antimicrob Chemother 2008;61(6):1359-1361.
54. Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 200811;22(2):F1-F9.
55. Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviralnaïve HIV-infected patients. AIDS 2008;30;22(3):385-393.
56. Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ ritonavir-based regimen is non-inferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr 2009; 50(5):474-481.
57. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twicedaily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial. J Infect Dis 2004; 189(2):265-272.
58. Molina JM, Podsadecki TJ, Johnson MA, et al. A lopinavir/ritonavir- based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses 2007;23(12):1505-1514.
59. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346(26):2039-2046.
60. Murphy RL, da Silva BA, Hicks CB, et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1- infected patients. HIV Clin Trials 2008;9(1):1-10.
61. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of fourdrug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349(24): 2304-2315.
62. Bierman WF, van Agtmael MA, Nijhuis M, et al. HIV mono therapy with ritonavir-boosted protease inhibitors: A systematic review. AIDS 2009;23(3):279-291.
63. Ananworanich J, Gayet-Ageron A, Ruxrungtham K, et al. Longterm efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther 2008;13(3):375-380.
64. Marin-Niebla A, Lopez-Cortes LF, Ruiz-Valderas R, et al. Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients. Anti - microb Agents Chemother 2007;51(6):2035-2042.
65. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: A non-inferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009; 50(4):367-374.
66. Walmsley SL, Cotte L, Rusconi S, et al. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. AIDS 2007;21(16):2245-2248.
67. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir- ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1- infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug resistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet 2006;368(9534):466-475.
68. Markowitz M, Slater LN, Schwartz R, et al. Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study. J Acquir Immune Defic Syndr 2007; 45(4):401-410.
69. Gathe JC Jr, Pierone G, Piliero P, et al. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatmentexperienced HIV type-1 infected patients. AIDS Res Hum Retroviruses 2007;23(2):216-223.
70. Davidson I, Beardsell H, Smith B, et al. The frequency and reasons for antiretroviral switching with specific antiretroviral associ ations: The SWITCH study. Antiviral Res 2010;86(2):227-229.
71. Malan DR, Krantz E, David N, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naïve patients. J Acquir Immune Defic Syndr 2008;47(2):161-167.
72. Calza L, Manfredi R, Colangeli V, et al. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtri - citabine in patients with hyperlipidemia switched from stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care 2009;23(9):691-697.
73. Naggie S, Hicks C. Protease inhibitor-based antiretroviral therapy in treatment-naïve HIV-1-infected patients: The evidence behind the options. J Antimicrob Chemother 2010;65(6):1094-1099.
74. Eron JJ, Young B, Cooper DA, et al. Switch to raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): Two multicentre, double-blind, randomised controlled trials. Lancet 2010;375(9712):396-407.
75. British Association for Sexual Health and HIV. Sexually Transmitted Infections: UK National Screening and Testing Guidelines. 2006. Available at: www.bashh.org/documents/59/59.pdf. Accessed May 28, 2010.
76. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipo - dystrophy. Arch Intern Med 2000:160:2050-2056.
77. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV health care in the HAART era. AIDS 2010;24(17):2705-2715.
78. Brogan AJ, Mrus J, Hill A, et al. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States (Abstract). HIV Clin Trials 2010;11(3):133-144.
79. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.